KEAP1 and neoplasm: Probst et al. [36] demonstrated that pharmacological Keap1 inhibition by the synthetic triterpenoid RTA 408, is distinct from those resulting from the loss of functional Keap1 in tumor cells and does not increase cellular proliferation or survival.